跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 133 条关于
“mIDH1”
全部
133
临床试验
113
药物
4
机构
0
资讯
16
2年前
Rigel Pharmaceuticals Initiates Phase Ib/II Trial of REZLIDHIA Combination Therapy for mIDH1 AML
去年
Rigel Pharmaceuticals Reports Strong Growth with TAVALISSE and REZLIDHIA in 2024, Expands Global Reach
去年
Rigel Pharmaceuticals Unveils Promising Final Data from GAVRETO and REZLIDHIA Clinical Trials at ASCO and EHA 2025
去年
Nuvation Bio Secures $250M Financing Package to Launch Novel Lung Cancer Drug Taletrectinib
去年
Over 120 Pipeline Therapies Target Acute Myeloid Leukemia as Research Intensifies
去年
Real-World Data Confirm Ivosidenib Efficacy in IDH1-Mutated Cholangiocarcinoma
去年
Olutasidenib Plus Azacitidine Shows Promise in IDH1-Mutated Relapsed/Refractory AML
去年
Olutasidenib Maintenance Therapy Demonstrates Sustained Remission in IDH1-Mutated AML Patients
去年
Vorasidenib Confirms Efficacy and Safety in IDH1/2-Mutant Diffuse Glioma
4年前
FDA Approves Ivosidenib Plus Azacitidine for IDH1-Mutated Acute Myeloid Leukemia
第 1 页,共 2 页
上一页
下一页